RepliCel Life Sciences to Present at Biotech Showcase(TM) 2014
09 Janeiro 2014 - 10:50AM
Marketwired
RepliCel Life Sciences to Present at Biotech Showcase(TM) 2014
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan 9, 2014) -
RepliCel Life Sciences Inc. (OTCQB:REPCF)(CNSX:RP), a clinical
stage biopharmaceutical company focused on developing therapies to
address conditions associated with cellular deficits, today
announced that CEO David Hall will present at the Biotech Showcase™
2014 investor and partnering conference to be held January 13-15,
2014 in San Francisco, at the Parc 55 Wyndham Hotel. Mr. Hall will
discuss RepliCel's autologous cell therapies for treating
tendinosis and androgenetic alopecia at 2:30 p.m. PST on January
13, 2014. A copy of the presentation will be added to RepliCel's
website and can be viewed here once posted.
About the Biotech Showcase
The Biotech Showcase is an investor and partnering conference
devoted to providing private and public biotechnology and life
sciences companies with an opportunity to present to, and meet
with, investors and pharmaceutical executives.
About RepliCel Life Sciences
RepliCel is a clinical stage biopharmaceutical company focused
on developing autologous cell therapies. RepliCel Tendon-01
(RCT-01) is a cell therapy for the treatment of chronic tendon
injuries. RepliCel Hair-01 (RCH-01) is a cellular treatment for
androgenetic alopecia (pattern baldness). Shiseido Company, Limited
has an exclusive geographic license for RCH-01 in certain Asian
countries including Japan, China and South Korea. Both product
candidates are based on RepliCel's innovative technology which
utilizes cells isolated from a patient's own healthy hair follicles
to address specific cellular deficits. For additional information
please visit www.replicel.com.
Notice Regarding Forward Looking Statements
This press release contains projections and forward-looking
statements, as that term is defined under applicable securities
laws. Statements in this press release, which are not purely
historical, are forward-looking statements and include the
following: (i) that the Company will conduct further human clinical
trials; (ii) that ongoing research collaboration will be conducted
by the Company and Shiseido for the continued improvement of the
technology; (iii) that a commercial, safe and effective hair
regenerative treatment will be developed and commercialized; (iv)
that the Company and Shiseido will develop further improvements to
the technology; (v) that the Company will undertake and enter into
development and collaboration agreements for the development of its
technologies; and (vi) and that the Company's technology will
rejuvenate damaged hair follicles leading to the growth of new
healthy hair fibers. These statements are only predictions and
involve known and unknown risks which may cause actual results and
the Company's plans and objectives to differ materially from those
expressed in the forward-looking information, including: that
negative results from the Company's clinical trials may impact
further clinical trials, development, approval and
commercialization of the technology; the effects of government
regulation on the Company's business, including the future
development of the technology; risks associated with the Company's
ability to obtain and protect rights to its intellectual property;
risks and uncertainties associated with the Company's ability to
raise additional capital; that the Company may not be able to find
other parties will to participate in the development and
collaboration of its technologies, and other factors beyond the
Company's control. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot guarantee future results, levels of activity
or performance. Further, any forward-looking statement speaks only
as of the date on which such statement is made, and, except as
required by applicable law, the Company undertakes no obligation to
update any forward-looking statement to reflect events or
circumstances after the date on which such statement is made or to
reflect the occurrence of unanticipated events. New factors emerge
from time to time, and it is not possible for management to predict
all of such factors and to assess in advance the impact of such
factors on the Company's business or the extent to which any
factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statement. Readers should consult all of the information set forth
herein and should also refer to the risk factor disclosure outlined
in the Company's annual report on Form 20-F for the fiscal year
ended December 31, 2012 and other periodic reports filed from
time-to-time with the Securities and Exchange Commission on Edgar
at www.sec.gov and with the British Columbia Securities Commission
on SEDAR at www.sedar.com.
RepliCel Life SciencesTammey GeorgeDirector of
Communications604-248-8696tg@replicel.comwww.replicel.comWestwicke
Partners, LLCStefan Loren, Ph.D.Managing Director(443)
213-0507sloren@westwicke.comWestwicke Partners, LLCRobert H.
UhlManaging Director(858) 356-5932robert.uhl@westwicke.com
RepliCel Life Sciences (CE) (USOTC:REPCF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
RepliCel Life Sciences (CE) (USOTC:REPCF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024